These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 17126525)

  • 1. An improved in vitro model to characterize invasive growing cancer cells simultaneously by function and genetic aberrations.
    Jung V; Wullich B; Kamradt J; Stöckle M; Unteregger G
    Toxicol In Vitro; 2007 Mar; 21(2):183-90. PubMed ID: 17126525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization.
    Laitinen S; Karhu R; Sawyers CL; Vessella RL; Visakorpi T
    Genes Chromosomes Cancer; 2002 Sep; 35(1):66-73. PubMed ID: 12203791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
    Man YG; Gardner WA
    Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer.
    Davies G; Ablin RJ; Mason MD; Jiang WG
    J Exp Ther Oncol; 2007; 6(3):257-64. PubMed ID: 17552366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maspin reduces prostate cancer metastasis to bone.
    Hall DC; Johnson-Pais TL; Grubbs B; Bernal R; Leach RJ; Padalecki SS
    Urol Oncol; 2008; 26(6):652-8. PubMed ID: 18367129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis of multifocal prostate cancer by comparative genomic hybridization.
    Kobayashi M; Ishida H; Shindo T; Niwa S; Kino M; Kawamura K; Kamiya N; Imamoto T; Suzuki H; Hirokawa Y; Shiraishi T; Tanizawa T; Nakatani Y; Ichikawa T
    Prostate; 2008 Dec; 68(16):1715-24. PubMed ID: 18781578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
    Zon G; Barker MA; Kaur P; Groshen S; Jones LW; Imam SA; Boyd VL
    Anal Biochem; 2009 Sep; 392(2):117-25. PubMed ID: 19505431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor and invasion in prostate cancer.
    Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
    Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial artificial chromosome array-based comparative genomic hybridization using paired formalin-fixed, paraffin-embedded and fresh frozen tissue specimens in multiple myeloma.
    Lennon PA; Zhuang Y; Pierson D; Zhang X; Williams C; Perez C; Lin P
    Cancer; 2009 Jan; 115(2):345-54. PubMed ID: 19109814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative analysis of genomic aberrations associated with prostate cancer progression.
    Kim JH; Dhanasekaran SM; Mehra R; Tomlins SA; Gu W; Yu J; Kumar-Sinha C; Cao X; Dash A; Wang L; Ghosh D; Shedden K; Montie JE; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2007 Sep; 67(17):8229-39. PubMed ID: 17804737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparanase promotes bone destruction and invasiveness in prostate cancer.
    Zhou Y; Song B; Qin WJ; Zhang G; Zhang R; Luan Q; Pan TJ; Yang AG; Wang H
    Cancer Lett; 2008 Sep; 268(2):252-9. PubMed ID: 18487013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic changes in pT2 and pT3 prostate cancer detected by comparative genomic hybridization.
    Fukasawa S; Kino M; Kobayashi M; Suzuki H; Komiya A; Imamoto T; Hirokawa Y; Shiraishi T; Takiguchi M; Ishida H; Shindo T; Seki N; Ichikawa T
    Prostate Cancer Prostatic Dis; 2008; 11(3):303-10. PubMed ID: 17923855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer.
    Bandyopadhyay S; Wang Y; Zhan R; Pai SK; Watabe M; Iiizumi M; Furuta E; Mohinta S; Liu W; Hirota S; Hosobe S; Tsukada T; Miura K; Takano Y; Saito K; Commes T; Piquemal D; Hai T; Watabe K
    Cancer Res; 2006 Dec; 66(24):11983-90. PubMed ID: 17178897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of myopodin expression reduces invasion and motility of PC-3 prostate cancer cells.
    De Ganck A; De Corte V; Bruyneel E; Bracke M; Vandekerckhove J; Gettemans J
    Int J Oncol; 2009 May; 34(5):1403-9. PubMed ID: 19360353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of hyaluronidase expression, invasiveness and tubule formation promotion in ER (-) and ER (+) breast cancer cell lines in vitro.
    Wang XY; Tan JX; Vasse M; Delpech B; Ren GS
    Chin Med J (Engl); 2009 Jun; 122(11):1300-4. PubMed ID: 19567141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT1 silencing affects locus specific DNA methylation and increases prostate cancer derived PC3 cell invasiveness.
    Yaqinuddin A; Qureshi SA; Qazi R; Farooq S; Abbas F
    J Urol; 2009 Aug; 182(2):756-61. PubMed ID: 19539327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
    Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
    Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
    Festuccia C; Muzi P; Gravina GL; Millimaggi D; Speca S; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Int J Oncol; 2007 Jan; 30(1):193-200. PubMed ID: 17143529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gain of chromosome X in prostatic atrophy detected by CGH and FISH analyses.
    Yildiz-Sezer S; Verdorfer I; Schäfer G; Rogatsch H; Bartsch G; Mikuz G
    Prostate; 2007 Mar; 67(4):433-8. PubMed ID: 17219381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
    Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.